Thymosin Alpha-1: The Definitive Guide

What is thymosin alpha-1?

Thymosin alpha-1 (often shortened to TA1 or Tα1) is a lab-made peptide, a chain of 28 amino acids, that copies a small protein first found in the thymus, the gland where T cells mature. As a medicine it is called thymalfasin and sold as Zadaxin, a prescription injection for chronic hepatitis B. Online it is sold as a "research peptide" for immune support, frequent colds, long COVID and autoimmune conditions. [1], [2]

Researchers first purified it in 1977 from thymosin fraction 5, a crude extract of calf thymus. Today's drug is made by chemical synthesis, with an acetyl group on its first amino acid as in the natural peptide. Its effects center on the immune system, although the label says its mechanism "is not completely understood". [1], [3]

Thymosin alpha-1 is a registered medicine in some countries and investigational in others. Singapore and Indonesia license it for chronic hepatitis B (and, in Singapore, hepatitis C alongside interferon), and Italy licenses it to help the flu vaccine work in people with weakened immunity. It is not approved by the US Food and Drug Administration (FDA). The popular claim that it is "approved in over 35 countries" comes from a 2014 manufacturer report that the FDA says it cannot verify. [2], [3], [4], [1]

It is not the same as thymosin beta-4 or TB-500, a different thymus protein sold for tissue repair. See how they compare.

Typical Thymosin Alpha-1 Protocols

On every current label the adult dose is the same: 1.6 mg injected subcutaneously twice a week, 3–4 days apart. Only the course changes with the use, from two 4-week blocks around flu vaccination to 6–12 months for hepatitis. Each vial is mixed with the 1 mL of sterile water supplied, immediately before use, and it must not be injected into a vein. [3], [2], [1]

What schedules do protocol websites describe?

Outside those countries, most people use a research-grade powder bought online, not the licensed product. These schedules come from dosing websites and clinics.

The most common schedule in the reviewed sources is the label's own: 1.6 mg by subcutaneous injection twice a week, 3–4 days apart, usually for 8–12 weeks when it is not being used for hepatitis. [8], [6], [9], [10], [11], [12], [13]

Read these cautions before the numbers. The label dose comes from trials in patients with hepatitis, sepsis, cancer and weak vaccine responses. No study has tested any of these schedules in healthy people, or for colds, allergies, long COVID or autoimmune disease. [1]

• Not with deliberate immune suppression. The label rules it out for transplant recipients and others whose immune system is being suppressed on purpose, unless the benefit clearly outweighs the risk. [2]
• Autoimmune disease. Italy's label says use in autoimmune disease must be judged case by case, and people describe flares after starting it, including one urgent-care visit after a single 0.5 mg dose. The most careful advice in community education groups is never to start during a flare. [1], [14]
• Do not stop or delay prescribed treatment to try it. That includes biologics, immunosuppressants and antibiotics; it has never been tested as a replacement for any of them. In community education groups, some people describe doing exactly this. A patient on a cancer immunotherapy developed a life-threatening immune reaction after it was added. [15]
• Children, pregnancy and breastfeeding. Italy's label says not to use it in children and rules it out in pregnancy and breastfeeding; its safety under 18 has not been established. [1], [3]
• Research vials are not the licensed product. The FDA found research and compounded thymosin alpha-1 poorly characterized and warned it may trigger immune reactions. The licensed vial holds 1.6 mg per mL; the peptide dissolves only up to about 2 mg per mL, yet research vials are often mixed several times stronger and turn cloudy. [1], [16]
• Read the units. mcg means micrograms; 1.6 mg is 1,600 mcg. A daily 500 mcg dose and a twice-weekly 1.6 mg dose are different schedules, not interchangeable amounts. On an insulin syringe, a unit measures liquid, not peptide; check any amount with the reconstitution calculator.

Titration Changing the amount in steps

The labels use a fixed dose, adjusted only for people under 40 kg (40 mcg per kg). [2] The one trial that compared doses found 0.8 mg and 1.6 mg twice a week worked about equally in hepatitis B. [17] Several trials started with 1.6 mg daily for 1–2 weeks before switching to twice a week. [18], [19] Websites either start low for a week (300 mcg daily, then 500 mcg) or start with a daily loading phase. [5], [7]

Breaks and cycles

The hepatitis B label gives 6 months without interruption and names no break; the Italian vaccine schedule leaves a 4-week gap between two courses. Websites add 8–12 weeks on and 4–8 weeks off, two or three courses a year, or seasonal courses in autumn and spring. One notes that no cycling schedule has been studied. [3], [1], [6], [12], [7], [20], [10]

Low, mid and high are alternatives, not steps to move through. The cited references give the full details.

Where protocols differ: daily or twice weekly, bursts and breaks ↓

What is thymosin alpha-1 commonly used for?

Most people who look into thymosin alpha-1 online want fewer colds and flu, a faster recovery from infections, relief from long COVID, ME/CFS (myalgic encephalomyelitis, also called chronic fatigue syndrome) or Lyme disease, fewer allergies, or calmer autoimmune disease. Compounded versions are marketed for all of these. [1], [27], [28]

Where it is licensed, it is prescribed for chronic hepatitis B. Most of its recent trials come from China, in sepsis, severe pancreatitis, liver disease and cancer. [2], [29], [30]

These two groups of uses rest on different evidence. The licensed uses come from trials in patients, and even those results are mixed. The popular uses rest on personal accounts, immune-cell measurements and animal research; none has been tested in a trial. The sections below keep them apart.

Chart listing conditions studied with thymosin alpha-1, the size of the main study for each and its result: no difference in deaths in the largest sepsis trial and no fewer pancreatic infections in the pancreatitis trial, uncertain effects in hepatitis B, melanoma and COVID-19, and a signal only in a small open-label liver-failure trial. Popular uses such as colds, allergies, long COVID and autoimmune disease have no trials.

Doserly

Where the human evidence is

Largest or most informative study for each condition

Chronic hepatitis B

StudyCochrane review, 2026 (10 trials)People1,349ResultUncertain Authors "not sure" of any effect; evidence certainty very low or low

Sepsis (intensive care)

StudyTESTS, 2025, placebo-controlledPeople1,106ResultNo difference Deaths by day 28: 23.4% vs 24.1%

Severe acute pancreatitis

StudyTRACE, 2022, placebo-controlledPeople508ResultNo difference Pancreatic infection: 15.7% vs 18.1%

Advanced melanoma (add-on to chemotherapy)

StudyRandomized trial, 2010People488ResultUncertain Median survival 9.4 vs 6.6 months; not statistically significant

Liver failure from hepatitis B

StudyOpen-label trial, 2022People120ResultSignal, open-label 90-day transplant-free survival 75.0% vs 53.4%; not significant in a second analysis

COVID-19 in hospital

StudyMeta-analysis, 2023 (9 studies, mostly observational)People5,352 patient outcomesResultUncertain No effect on deaths; individual studies conflict

Flu vaccine in older men

StudyPlacebo-controlled trial, 1989People90ResultMarker only Strong antibody response 69% vs 52%; antibodies, not infections, were measured

HIV immune recovery

StudyRandomized pilot, 2003People20ResultNo difference No difference in CD4 T-cell counts at 12 weeks

Popular online uses with no trials

• Colds and flu in healthy people
• Allergies and sinus problems
• Long COVID
• ME/CFS
• Lyme disease
• Autoimmune disease
• Anti-ageing

Largest or most informative study per condition; people counts are those randomized or enrolled. Most trials were in hospital patients or people with chronic hepatitis.

The largest placebo-controlled trials found no difference, and the most popular online uses have never been tested.

Colds, flu and "immune support"

This is the most common reason people try it, and there is no trial behind it. No study has tested whether thymosin alpha-1 prevents or shortens colds or flu in healthy people. [1]

The nearest evidence comes from vaccine studies. In a 1989 trial of 90 men aged 65–99, twice-weekly injections around a flu shot raised the share with a strong antibody response from 52% to 69%, mostly in men aged 77 and older. Antibody levels are not the same as fewer infections, and the FDA judged the vaccine studies too small and too old to show a benefit. A US trial now recruiting is testing 4.8 mg before a COVID-19 vaccine booster in older adults. [31], [1], [32]

Long COVID, ME/CFS and Lyme disease

People with these conditions are among the most active users online, and they report the widest range of outcomes, from large improvements to crashes after small doses (see what people report). No trial has tested thymosin alpha-1 in any of them. The FDA found no clinical studies in ME/CFS, and the COVID-19 studies tested the acute infection, mostly in hospital, not long COVID. [1], [33], [28], [14]

Allergies, sinus problems and histamine intolerance

Allergy relief is one of the most common positive stories online, often with allergy medicines or other peptides at the same time. It has not been studied. [27], [34], [35] Italy's label advises caution in people with atopy (a tendency to allergies such as hay fever, asthma or eczema) or past allergic reactions. [1]

Autoimmune conditions

People with lupus, psoriasis, Hashimoto's thyroiditis, rheumatoid arthritis and other autoimmune diseases use it on the idea that it "balances" the immune system. That idea has not been tested: there are no trials of thymosin alpha-1 as a treatment for autoimmune disease. [1]

One Italian study found lower blood levels of thymosin alpha-1 in 200 people with lupus, rheumatoid arthritis or psoriatic arthritis than in 120 blood donors, but a low level does not show that adding more helps. [36] Its known actions stimulate immune cells, Italy's label says autoimmune use must be judged case by case, and flares have been reported (see risks). [1], [14]

Hepatitis B and C

Chronic hepatitis B is the main licensed use. Trials from the 1990s and 2000s gave mixed results, and the 2026 Cochrane review of 10 trials concluded that its authors were "not sure" it helps. Hepatitis C use was always alongside interferon, a treatment that has since been replaced by antiviral tablets. [2], [37], [1] The human research section gives the details.

Sepsis and severe infections in hospital

Sepsis is a dangerous whole-body reaction to infection. Thymosin alpha-1 was tested as an add-on to intensive care, and the largest trial, 1,106 adults in 22 Chinese intensive care units, found no difference in deaths. [29] A trial in severe pancreatitis also found no benefit. [30] These were hospital treatments given alongside antibiotics, not evidence for home use during an illness.

Cancer

It has only ever been studied as an add-on to cancer treatment, never as a treatment on its own. A 488-person melanoma trial found a trend toward longer survival that fell short of statistical significance, and a Cochrane review found no clear survival effect across cancer trials. [38], [39] Recent Chinese trials test 4.8 mg per dose alongside chemotherapy and immunotherapy, without posted results. [40] One patient on a cancer immunotherapy had a life-threatening immune reaction after it was added. [15]

Other uses you may come across

Small studies have looked at flare-ups of COPD (chronic obstructive pulmonary disease), replanting knocked-out teeth, immune recovery in HIV and depression in people with an antibody deficiency, and a trial in repeated IVF implantation failure is recruiting. Hair regrowth and anti-ageing claims appear only in personal accounts and marketing. [41], [42], [19], [43], [44], [45]

Where do thymosin alpha-1 protocols differ?

Thymosin alpha-1 schedules disagree mainly on how often to inject: twice a week, as on the label, or a smaller amount every day. They also split on short daily "bursts", course length and breaks. Here is what changes between them and why it matters.

Twice a week or every day?

The label gives 1.6 mg twice a week. A second group of websites gives 300–500 mcg every day instead, reasoning that 500 mcg a day adds up to about 3.5 mg a week, which one page calls "consistent with clinical dosing ranges". The earliest dated version of this idea is a 2024 page that split the weekly amount into daily doses because thymosin alpha-1 leaves the blood quickly. [5], [46]

Equal weekly totals do not mean equal exposure. After an injection, blood levels peak at about 2 hours and are back to baseline within 24 hours, so a 1.6 mg injection and a 500 mcg injection each produce their own peak, gone by the next day. [3], [47] No study has compared daily with twice-weekly dosing, so nobody knows whether either pattern works better. One website's 1.5 mg "five days on, two days off", described as the same weekly total, is actually 7.5 mg a week, more than twice the label's 3.2 mg. [20]

Weekly calendar comparing three thymosin alpha-1 schedules: the label's 1.6 mg on two days (3.2 mg a week), 500 mcg every day (3.5 mg a week) and 1.5 mg on five days (7.5 mg a week). Each dose clears from the blood within a day. No study has compared these schedules.

Doserly

Similar weekly totals, very different weeks

One example week per schedule; days are illustrative

Label schedule · 3.2 mg a week

Zadaxin label: 1.6 mg twice a week, 3–4 days apart

• Mon1.6 mg
• Tue–
• Wed–
• Thu1.6 mg
• Fri–
• Sat–
• Sun–

Daily microgram schedule · 3.5 mg a week

Dosing website: 500 mcg every day from week 2

• Mon500 mcg
• Tue500 mcg
• Wed500 mcg
• Thu500 mcg
• Fri500 mcg
• Sat500 mcg
• Sun500 mcg

Five days on, two off · 7.5 mg a week

Dosing website: 1.5 mg a day, Monday to Friday

• Mon1.5 mg
• Tue1.5 mg
• Wed1.5 mg
• Thu1.5 mg
• Fri1.5 mg
• Sat–
• Sun–

Its page calls this the same weekly total as the label; it is more than twice.

Dot area is proportional to the amount injected. Blood levels after each injection peak at about 2 hours and are back to baseline within 24 hours (label; 1999 study).

Similar weekly totals do not mean equal exposure, and no study has compared these schedules.

Is 1.6 mg, 1.5 mg or 1 mg the right amount?

1.6 mg is simply the content of one licensed vial. Research powders come in 5 and 10 mg vials, so many people round to 1.5 mg or 1 mg to make a vial divide evenly, and 1–1.5 mg are the amounts people report most often in public forums and community education groups. [27], [34], [48]

The one trial that compared doses, in 316 Japanese people with hepatitis B, found 0.8 mg and 1.6 mg twice a week worked about equally overall, although people with advanced liver scarring did better on 1.6 mg. [17], [1] That is the only human evidence for a lower dose, and it comes from a liver disease, not from healthy use.

Loading courses and short "bursts" when illness starts

Several trials started with daily injections: 1.6 mg a day for the first 1–2 weeks, then twice a week, in liver failure from hepatitis B, in HIV and in a small depression study. [18], [19], [43] Websites borrow this as a "loading" phase, sometimes at 3.2 mg a day. [7], [49], [50]

Many users go further and inject about 1 mg every day for up to 10 days at the first sign of a cold or flu, or when someone at home falls ill. One dosing site describes daily 1 mg courses of 10–30 days as community practice rather than trial dosing, and in community education groups this is the most repeated pattern after the twice-weekly schedule. [8], [51], [52] No study has tested it for colds, flu or sore throats, and it does not replace antibiotics for a bacterial infection. The intensive twice-daily doses in sepsis trials were given to intensive care patients alongside antibiotics, and the largest trial found no survival benefit. [29]

How long, and are breaks needed?

For hepatitis B the label says 6 months (52 doses) without interruption, and a Taiwanese trial found a 26-week course did at least as well as 52 weeks. [3], [53] Websites instead describe 8–12 weeks on and 4–8 weeks off, two or three courses a year, or seasonal courses in autumn and spring. [6], [7], [12], [20]

Community education groups disagree just as much: some teach continuous year-round use, others fixed courses stopped once an illness clears, or regular breaks meant to keep the immune system from being overstimulated. No study has tested whether breaks matter, and one dosing page says so plainly. [10]

Morning or evening?

The labels say nothing about timing. Some community education groups advise bedtime doses and others morning doses, and people describe lying awake after an evening injection; one protocol page prefers morning. [13], [54] There is no evidence either way.

What about 3.2, 4.8 or 6.4 mg?

Larger single doses come from supervised trials: 3.2 mg in HIV and in some sepsis studies, 1.6–6.4 mg added to chemotherapy in melanoma, and 4.8 mg in recent Chinese cancer trials that have not posted results. [55], [56], [38], [40] In an early cancer study, single injections into a muscle of up to about 16 mg did not reach a dose that caused serious side effects. [1] One website extends to 6.4 mg twice a week "in severe cases under medical supervision". [57] None of these doses has been tested for everyday use.

How do milligrams convert to syringe units?

Research thymosin alpha-1 is sold as a freeze-dried powder that is mixed with sterile or bacteriostatic water before use (reconstitution). On a U-100 insulin syringe, units measure volume, not drug. For example, a 10 mg vial (10,000 mcg) mixed with 5 mL holds 2,000 mcg per mL, or 20 mcg per unit, so 1.6 mg is 80 units and 500 mcg is 25 units. The same vial mixed with 2 mL, as one dosing page shows, holds 5 mg per mL, and 1.6 mg becomes 32 units. [8]

The licensed product holds 1.6 mg in 1 mL, and the FDA says the peptide dissolves only up to about 2 mg per mL, so strong mixes may not fully dissolve (see storage). [3], [1] Doserly's reconstitution calculator works out the units for any vial and shows each step.

What happens when you stop thymosin alpha-1?

No withdrawal effects or rebound have been described in the labels or trials, but no study was designed to look for them. [3], [1]

• Hepatitis B responses can arrive after stopping. On the label and in trials, more people cleared the virus in the 6–12 months after treatment than by its end, which is why the label asks for blood tests 2, 4 and 6 months after the last dose. [3], [53]
• Immune changes fade. In a five-person study of depression in people with an antibody deficiency, the immune-cell changes did not last through an 8-week break, and depression returned in the two most severe cases. [43]
• Personal accounts. Several people describe allergy or fatigue relief returning within days or weeks of stopping. A few describe benefits lasting months, and one described benefits lasting over a year after 2.5 years of use. [34], [58], [59], [60], [33] In community education groups, people describe the same split.

The breaks websites recommend are a convention; no study has tested them. [10]

How is thymosin alpha-1 taken, and how long does it last?

By subcutaneous injection. Every current label and nearly every trial used this route; the labels rule out injection into a vein, and only Italy's vaccine use allows injection into a muscle. [3], [2], [1] The FDA found compounded thymosin alpha-1 sold as nasal sprays as well as injections, but no study has measured how much of a nasal or swallowed dose reaches the blood (its bioavailability). [1]

The labels name no preferred injection site, and no study has compared sites or tested an effect at the injection site.

How long does thymosin alpha-1 last in the body?

Its half-life in the blood is about 2 hours. In healthy volunteers, levels peaked 1–2 hours after an injection and returned to baseline within 24 hours, with no build-up over 5–7 daily doses of 1.6–16 mg; 31–60% of each dose left the body in urine. [3], [47] In most volunteers, the body's own levels were too low to measure with the same test. [47]

How long an effect lasts is a different question. The twice-weekly label schedule, and hepatitis B responses that appear months after the last dose, suggest effects outlast blood levels, but no human study has measured how long an immune effect lasts after a single injection. [3], [53] This is the core of the daily versus twice-weekly disagreement.

Is research "TA1" the same as Zadaxin?

Not necessarily. Zadaxin is a finished medicine: 1.6 mg of peptide with mannitol and a phosphate buffer at pH 6.8, made to a regulator's standards. [3] Research powders are sold as the free peptide or as an acetate salt, which the FDA treats as separate substances. It judged neither well characterized and found no data on their impurities, clumping (aggregation) or bacterial toxins. [1]

Even licensed formulations differ: in a 9-person study, one of three products (Timosina) produced higher blood levels than the other two at the same dose. [47] A 2022 laboratory study found 23 related impurities in thymalfasin materials, more than half from the breakdown of its last amino acid. [66] A long-acting "pegylated" version tested in China is a different molecule. [67]

How should thymosin alpha-1 be stored, and how long does it last?

For the licensed product the answer comes from the label. For research powders and mixed vials, no shelf life for human use has been established.

• Licensed vials (Zadaxin). Keep at 2–8 °C; unopened shelf life is 3 years. Mix with the 1 mL of sterile water supplied immediately before use and use it right away. [3], [2]
• Research powder. Supplier data quoted by the FDA say the dry powder is stable for three weeks at room temperature and should be kept dry below −18 °C for long-term storage; once mixed, 2–7 days at 4 °C, or frozen with an added carrier protein. These are laboratory-supplier statements, not a drug label. [1]
• Mixed research vials. Dosing websites give anything from "use immediately" or 48 hours to 7, 14–21, 28 or 30 days, sometimes two different figures on the same page. None cites a stability test for a vial mixed with bacteriostatic water at home. [24], [22], [49], [68], [8], [9], [63]
• Cloudy or gelled vials. These are a frequent complaint, especially when a 5–10 mg vial is mixed with 0.5–1 mL of water, several times the licensed strength. Advice to fix it with acid, baking soda or buffered saline conflicts and has not been tested. Community education groups advise against injecting a solution that stays cloudy, and the FDA links clumped peptide to immune reactions. [16], [1]

Bar chart comparing thymosin alpha-1 solution strengths: the licensed vial at 1.6 mg per mL, near the peptide's reported solubility of about 2 mg per mL, against website examples of 3.3 and 5 mg per mL and research vials mixed at 5 to 10 mg per mL, where cloudy or undissolved vials are reported.

Doserly

How strong is the mix?

Concentration in mg per mL; not a mixing instruction

Reported solubility in water: about 2 mg per mL (free peptide), about 1 mg per mL (acetate salt).

Licensed Zadaxin · 1.6 mg/mL

1.6 mg in 1 mL

Compounded product proposed to the FDA · 3.0 mg/mL

FDA doubted this strength can be made because of limited solubility

Website example · 3.3 mg/mL

10 mg vial in 3 mL

Website example · 5.0 mg/mL

10 mg vial in 2 mL

Research vial in 1 mL · 5–10 mg/mL

5 or 10 mg vials; forum reports describe 1 mL mixes that would not fully dissolve

Concentrations are arithmetic from the stated vial content and water volume. This figure compares strengths; it is not a mixing instruction.

Website examples and common home mixes are about 2 to 6 times the licensed strength, above the reported solubility.

This guide does not cover mixing or injection technique; the Academy note below covers practical handling.

What do we actually know about thymosin alpha-1 in people?

More than for almost any other peptide sold online: dozens of trials in thousands of patients. But most are small, open-label (everyone knew who got the drug) or decades old, and the largest, best-designed trials found no clear benefit on the outcomes that matter most. None tested healthy people. [1], [29], [37]

Hepatitis B: what did the trials find?

The labels cite a pooled analysis of three trials (223 patients): 36% versus 19% responded a year after treatment. [3] A 2008 meta-analysis found it worked less well than interferon by the end of treatment but better 6 months later, the same delayed pattern. [73] Only the cirrhosis trial added it to a modern antiviral, and it found no benefit. [72]

Hepatitis C

With interferon, a 109-person US trial found more people with normal liver enzymes at the end of treatment (37.1% versus 16.2%) but few lasting responses (14.2% versus 8.1%); on its own it did not clear the virus in a 19-person pilot. [74], [75] Interferon has since been replaced by antiviral tablets, so these results say little about care today. [1]

Sepsis: what did the TESTS trial find?

The TESTS result was corrected in May 2025: the hazard ratio changed from 0.99 to 0.97, and older summaries and the PubMed abstract still show the first figure. [76] A 2025 meta-analysis of 11 trials found fewer deaths overall, but not when it was limited to high-quality or multicentre trials, and judged the evidence too small to settle the question. [77]

COVID-19

The evidence conflicts. A small Wuhan study reported fewer deaths in severe cases (11% versus 30%), a study of 771 critical cases found no difference once 522 of them were matched for how ill they were, and a 2,282-person cohort found treated patients less likely to recover. [78], [79], [80] Meta-analyses disagree, and a US pilot trial in 49 hospital patients found no significant difference in recovery before it stopped for slow enrolment. [81], [82], [83] In a prevention trial in kidney dialysis patients, 5 of 91 treated and 7 of 98 untreated people caught COVID-19, too few to draw a conclusion. [84]

Vaccines, HIV and immune recovery

These studies measured immune markers rather than infections. Older men given it with the 1986 flu vaccine more often had strong antibody responses (69% versus 52%), and dialysis patients had higher antibody levels three weeks after a pandemic flu vaccine, with no sign that the effect lasted. [31], [85], [1] In HIV, 3.2 mg twice a week for 12 weeks did not raise CD4 counts (a key T-cell count) more than no treatment. A 24-week single-group study in people whose CD4 counts had stayed low found no significant rise in the count itself, although the mix of T cells changed. [55], [19] The FDA found the vaccine studies too small, too old and measured with tests that do not show protection. [1]

Cancer

Always as an add-on. In 488 people with advanced melanoma, adding it to chemotherapy gave a median survival of 9.4 versus 6.6 months, a difference that fell short of statistical significance, with no extra side effects. [38] A 2011 Cochrane review found no clear survival effect across cancer trials, and lung and liver cancer studies are mostly small, retrospective or at unclear risk of bias. [39], [86], [87] A 2025 conference abstract, a low-grade source, reported 21 people with advanced solid tumours given it alongside radiotherapy, a checkpoint inhibitor and an immune-cell growth factor: tumours shrank enough to count as a response in 23.8% and no severe (grade 3 or higher) side effects were reported. With no comparison group and three other treatments, none of this can be credited to thymosin alpha-1. [130]

What are the registered studies planning?

Checked September 24, 2026: ClinicalTrials.gov lists 66 studies under its names, and only 2 have posted results. [67] These are plans, not results.

Has thymosin alpha-1 been tested in healthy people?

No. The only healthy-volunteer studies measured blood levels after injection. [47] None of the trials above enrolled healthy adults, and claims of stronger immunity, fewer colds or slower ageing in healthy people have not been tested. [1]

What do immune-cell results actually show?

Many studies report changes in T cells, dendritic cells or immune proteins. Those are markers, not outcomes. In HIV, the share of certain T cells improved without a clear rise in counts; in sepsis, a better immune marker (mHLA-DR) in the ETASS trial did not become a survival benefit in the larger TESTS trial. [19], [26], [29] When you read a claim, ask whether it measured a marker, fewer infections, or survival.

How might thymosin alpha-1 work?

Nobody knows exactly. The label says its mechanism "is not completely understood" and is thought to center on strengthening T-cell function, based mostly on laboratory and animal work. [3] Laboratory experiments often use concentrations far above the blood levels measured after an injection, so a finding in a dish may not happen in the body. [47], [89]

What does the thymus have to do with it?

The thymus is where young T cells learn which targets to attack. In laboratory tests, thymosin alpha-1 helped T cells mature, raised immune signalling proteins such as interferon-gamma and interleukin-2, and increased the activity of natural killer cells. In animals whose immune systems had been weakened by chemotherapy, radiation or tumours, it protected against infections and bone-marrow damage. [3] Whether the same happens in a healthy adult has not been measured.

Does it switch on dendritic cells?

In mice and in human cells in a dish, yes. It helped dendritic cells (immune "scouts" that show T cells what to attack) mature and send signals through toll-like receptors, sensors that detect germs, and it protected mice with weakened immune systems from a fungal infection. [90], [91]

Does it "balance" the immune system?

That is a common marketing word, and the evidence is mixed rather than supportive. In human cells in a dish, it strengthened responses to virus-like signals but damped responses to bacterial signals, and in mouse cells its effect depended on which other inflammatory signals were present. [92], [93]

It raised regulatory T cells, which calm immune responses, only at a laboratory concentration hundreds to more than a thousand times higher than blood levels after an injection. [89], [47] No study shows that it calms autoimmune disease in people. [1]

Does it affect cancer growth?

In laboratory tests it did not make tumour cells grow or turn normal cells cancerous, and a 2026 mouse study suggested it helps immune cells respond after chemotherapy. [94], [95] No long-term cancer (carcinogenicity) study has been done. [3]

What else has been reported?

A 2026 single-laboratory study reported that it binds a brain receptor involved in wakefulness (the orexin receptor) and protected brain tissue after stroke in mice. This is an early, unreplicated finding. [96]

What are the risks and unanswered questions?

Is thymosin alpha-1 safe?

At the licensed dose, in patients under medical care, trials found it well tolerated; outside that setting its safety is much less known. The label reports no clinically significant reactions in more than 2,000 treated people (under 1% of events judged drug-related), and in the largest trial, side effects were as common on placebo (66.4% versus 67.6%; serious events 26.8% versus 29.3%). [3], [29]

But the trials were short courses in hospitals and liver clinics, no long-term cancer study has been done, the FDA found no published animal toxicity studies beyond the manufacturer's brief summaries, and research powders are not the licensed product. [3], [1] The often-quoted "11,000 people with no safety concerns" comes from a narrative review that argued against FDA restrictions; it names the databases it searched but not how it chose its studies. [97]

What side effects have been reported?

People using research products also describe flu-like crashes, joint pain, anxiety and poor sleep; those accounts are covered in what people report.

Can thymosin alpha-1 trigger an autoimmune flare?

It might, and nobody has measured how often. It stimulates immune cells, the label urges caution with other immune-modulating medicines, and Italy's label says use in autoimmune disease must be judged case by case. [3], [1] People describe flares after starting it, including severe whole-body joint pain after a single 0.5 mg dose, and severe anxiety and night sweats in someone with an autoimmune history. [14], [33]

In community education groups, first-hand reports include spreading psoriasis, worsening thyroid autoimmunity and a returning nerve-pain condition. Educators there disagree: some call it the main peptide for autoimmune disease, while the most careful course material says to avoid it in Graves' disease, active lupus, vasculitis and myasthenia gravis or during a multiple sclerosis relapse, and never to start during a flare. That material also suggests a lower start (0.8 mg twice a week) and checking the disease's antibody and inflammation tests; the only human support for a lower dose is the hepatitis B comparison of 0.8 and 1.6 mg. [17]

Can it be combined with cancer immunotherapy, biologics or transplant drugs?

This is where the clearest warnings are. The label rules it out in people whose immune system is being deliberately suppressed, such as transplant recipients, unless the benefit clearly outweighs the risk. After stem-cell transplants, the FDA raised concerns about graft failure and graft-versus-host disease. [2], [1]

A 2026 case report described a life-threatening multi-organ immune reaction in a patient given it with a checkpoint inhibitor, a type of cancer immunotherapy. [15] A 2025 conference abstract on 21 people given it with a checkpoint inhibitor, radiotherapy and an immune-cell growth factor reported no severe (grade 3 or higher) side effects; it is a small report with no comparison group, so it cannot rule out rare reactions like that one. [130] With biologics for Crohn's disease, psoriasis or rheumatoid arthritis, combinations are unstudied and the two push the immune system in opposite directions; some people online ask whether to delay their biologic to try it. [100] Changes to these medicines belong with the prescribing specialist.

Could product quality change the risk?

Yes. The FDA found research and compounded thymosin alpha-1 "not well-characterized", with no data on impurities, clumping or bacterial toxins, and warned that such products may provoke the immune system to react against the peptide itself (immunogenicity). [1], [101] Health Canada has seized unauthorized vials labelled thymosin alpha-1 from online sellers. [102], [103] Mixes stronger than the licensed 1.6 mg per mL add a further risk of undissolved or clumped peptide (see storage).

Is thymosin alpha-1 legal? Is it FDA-approved?

Checked September 24, 2026. Rules differ by country and change quickly. A "research use only" label does not make a product legal to sell or safe to use.

United States. Thymosin alpha-1 is not an FDA-approved medicine. The key steps:

• Orphan designations. It holds four US orphan designations, a status that supports development for rare diseases and is not an approval. [1]
• 2023. It was placed in Category 2, "significant safety risks", of the FDA's list of substances nominated for pharmacy compounding. [104]
• 2024 FDA review. The nomination was withdrawn, but the FDA reviewed the free peptide and its acetate salt for 12 uses anyway and recommended against adding either to the list of ingredients pharmacies may compound. [1]
• December 4, 2024. The FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no for each form. An advisory vote is not a final agency decision. [105]
• Now. It is not in any category of the FDA's 503A compounding list (updated May 14, 2026). The FDA's safety-risk page lists it as "nominated but withdrawn" with an immune-reaction warning, it sits in the "nominated without adequate support" group for outsourcing facilities, and no final rule has been published. [106], [101], [107], [108]

Canada. Health Canada lists no authorized product. It named "Thymosin alpha" among seized unauthorized injectable peptides in August 2025 and "Thymosin Alpha-1 10 MG" in a December 2025 seizure, and warns that injectable peptides are prescription drugs. [109], [102], [103], [110]

Australia. No thymosin alpha-1 product is on the Australian Register of Therapeutic Goods, and the Therapeutic Goods Administration fined a company in 2020 for advertising it as a COVID-19 preventive. New Zealand's regulator said in June 2025 that it was not scheduled in Australia; we could not check the current Australian schedule. [111], [98]

New Zealand. "Thymic peptide hormones and their analogues", a group New Zealand's regulator defined to include thymosin alpha-1, became prescription medicines on 19 December 2025. [112], [98]

Europe. Authorized nationally in Italy to help the flu vaccine work in people with weakened immunity. Its 2002 EU orphan designation for liver cancer is not a marketing approval. [4]

Asia. A prescription medicine in Singapore and registered in Indonesia; the FDA also lists approvals in India and Hong Kong. [2], [3], [1]

Is thymosin alpha-1 banned in sport? Does it show up on a drug test?

It is not named on the World Anti-Doping Agency's 2026 or 2027 lists, which name thymosin beta-4 and TB-500 instead. Their S0 rule bans substances with no current government approval for human use; because thymosin alpha-1 is approved in several countries, it is unclear whether S0 covers it, and we found no anti-doping ruling or athlete case naming it. Competitive athletes should check with their anti-doping organization. [113], [114]

Who should be especially cautious?

The label and Italy's label rule out or warn about the first five groups. The others have not been studied, which is a reason for caution, not proof of harm.

• Transplant recipients and anyone on medicines that deliberately suppress the immune system. Ruled out by the label unless the benefit clearly outweighs the risk. [2]
• Pregnancy, breastfeeding and trying to conceive. Italy's label rules out pregnancy and breastfeeding; the Indonesian label allows it in pregnancy only "if clearly needed". The IVF trial now recruiting is not evidence of safety. [1], [3], [44]
• Children and teenagers. Italy's label says not to use it in children, and safety under 18 has not been established. [1], [3]
• Allergies. Caution in people with atopy or past allergic reactions (Italy's label). [1]
• Autoimmune disease. Case by case on Italy's label; flares are reported. [1], [14]
• Cancer, especially with immunotherapy. Only studied as an add-on under oncologists' care. [15]
• Hepatitis B or other liver disease. Liver enzyme flares need specialist monitoring. [3]
• A serious bacterial infection. In hospital trials it was given alongside antibiotics, never instead of them. [29] In community education groups, some people describe waiting on thymosin alpha-1 before filling an antibiotic prescription.
• Several new compounds at once. Stacks make any reaction impossible to attribute.
• Drug-tested athletes, because of the unclear S0 status. [113]

Has thymosin alpha-1 been tested alongside other medicines?

Not in formal interaction studies. The label says interactions "have not been fully evaluated", advises caution with other immune-modulating drugs and says not to mix it with any other drug; some people draw it into the same syringe as other peptides anyway. [3] Trials gave it alongside interferon, hepatitis B antivirals, chemotherapy and intensive care treatment; the FDA flagged thyroid changes with interferon as a possible interaction. [1]

In rats, two weeks of injections increased the activity of liver enzymes that break down some medicines (such as CYP2E1); whether this matters in people is unknown. [115] Nothing is known about combinations with other peptides such as LL-37, KPV or thymulin. Bring a complete list of everything you take to a pharmacist or doctor.

What should be monitored while using thymosin alpha-1?

Only the hepatitis B label sets tests, and they are hepatitis tests. For other uses, what exists is a record of what trials measured and what reports flagged, which can help you prepare questions for a clinician; it is not a personal testing plan.

What does the label ask for?

For hepatitis B: liver tests (ALT, albumin and bilirubin) regularly during treatment, and hepatitis B markers (the viral proteins HBeAg and HBsAg, and HBV DNA, the virus's genetic material) plus ALT at the end of treatment and 2, 4 and 6 months later. A temporary ALT rise to more than twice the starting level can happen; the label says to continue unless signs of liver failure appear. [3], [2]

What did the studies measure?

• T cells and other immune markers. CD4 and CD8 T-cell counts and types, natural killer cells and mHLA-DR (an immune marker in sepsis) in sepsis and HIV studies. [26], [19]
• Thyroid tests in hepatitis C trials that combined it with interferon. [1]
• Blood counts and blood chemistry in the dialysis vaccine study, which found no changes linked to thymosin alpha-1. [85]
• Antibody levels in vaccine studies. [31]

One protocol page suggests periodic lymphocyte panels (counts of T cells and natural killer cells) during long courses. [7] In community education groups, the most careful approach for people with autoimmune disease checks the disease's own antibody levels and inflammation markers such as CRP before starting and again after about 12 and 24 weeks.

Which signals matter, and why?

A severe allergic reaction, signs of liver failure in someone with hepatitis B (such as yellowing skin or eyes), or a rapidly worsening flare needs urgent medical care rather than tracking. [3]

These come from small studies and personal accounts, so they show what has been flagged, not what a person will experience.

What do people in public communities report?

Public forums and community education groups contain grateful stories, flat disappointments and a steady stream of crashes and flares, often in the same thread. Most people use research powders rather than the licensed product, and most take other peptides or medicines too. These are selected discussions, not a survey of everyone who has tried thymosin alpha-1.

What do the positive reports look like?

The typical success story is a winter without colds, or allergies that eased. One person on 1.5 mg twice a week since January noticed that their usually severe allergies had not appeared that spring; another described 1 mg twice a week for a month ending a spouse's cold-weather allergy for about a year; a teacher credited it with staying well at work. [27], [34], [119] In community education groups, the largest group of stories describes not catching illnesses that went around the household, usually on 1–1.6 mg two or three times a week.

The longest stories come from ME/CFS forums. One person used about 450 mcg daily, later three times a week, alongside thymosin beta-4, and described going from bedbound to running a few errands a week over 2.5 years. [33] Stories of eczema clearing, fewer herpes-like infections or better joint pain usually involve other peptides or treatments at the same time. [118], [120], [121]

How fast does it work, and how long does it last?

Accounts range from feeling different within hours (clearer sinuses the day after a first injection) to judging it over months. [60] Community education groups teach that immune goals take 8–12 weeks, yet most members use it in short bursts when they feel ill. After stopping, allergy and fatigue relief often returned within days or weeks. [34], [58], [59]

Does everyone notice something?

No. "Nothing happened" is a common story: one person with recurrent herpes tried up to 1 mg a day with no fewer outbreaks, another felt little after 18 months of twice-weekly injections for Lyme disease, and an ME/CFS forum member estimated that only about 1 in 10 people in their group benefited (a second-hand estimate, not a count). [117], [48], [122]

People also catch colds, flu, strep throat and sinus infections while taking it. [116], [34] In community education groups, one person's 10 days of daily injections did not stop what was later diagnosed as strep throat, and several people still needed antibiotics.

Does feeling worse mean it is working?

Not necessarily. Many users, especially with ME/CFS, long COVID or Lyme disease, describe crashes, flu-like aches, a sore throat or night sweats after doses as small as 150–500 mcg, and some call this a "herx". [28], [14], [33] That label is an interpretation: no study has shown that feeling worse on thymosin alpha-1 predicts a benefit.

Some people who pushed through got worse, including one who needed urgent care for joint pain after a single 0.5 mg dose. [14] Many respond by dropping to 50–200 mcg; one person tolerated 100 mcg five days a week but crashed at 150 mcg. [33]

What unwanted effects come up?

The recurring complaints are fatigue or post-dose crashes, flu-like aches, joint pain, headaches, nausea, dizziness, anxiety, poor sleep and a racing heart. Less common reports include tonsil stones with every course, and dizziness with brown-tinged urine that one person linked to an unverified overseas product. [123], [33], [119], [54] In community education groups, anxiety and sleeplessness cluster at larger or evening doses, and a few people describe diarrhoea or a skin flare.

Why do so many vials turn cloudy?

Cloudy, speckled or gelled vials are one of the most common practical complaints, in public forums and community education groups alike. The fixes people swap (adding acid, adding baking soda, buffered saline or simply more water) contradict each other, and none has been tested. [16] The problems cluster in mixes several times stronger than the licensed product; see storage.

How can you judge a thymosin alpha-1 story?

Ask: Was it the licensed product or a research powder, and was the vial clear? How many milligrams, rather than "units" or "cc"; several people describe reactions they later traced to a miscalculated dose. [51] What else changed: other peptides, allergy medicines, antibiotics, the end of a pollen season? Was an infection actually avoided, or just not caught that week? Did the person post again months later? Immune stories are especially hard to judge, because colds and allergies come and go on their own.

How does thymosin alpha-1 compare with TB-500, LL-37 and KPV?

These peptides are sold side by side for immunity and recovery, and TB-500 is often confused with thymosin alpha-1 because both come from the thymus family of peptides. Only thymosin alpha-1 is a licensed medicine anywhere.

No study has compared these peptides with each other or tested them together, so the table cannot say which works better or is safer. The popular "immune stack" pairs thymosin alpha-1 injections two or three times a week with daily LL-37, often with KPV; the combination is untested, and a stack makes any benefit or reaction impossible to attribute.

People online often ask how thymosin alpha-1 differs from thymalin and thymulin, two other thymus-derived products, and some treat them as interchangeable. Thymulin is a separate, zinc-bound thymus peptide that, New Zealand's regulator notes, does not appear to have entered clinical trials. [98], [129] Community education groups disagree on whether two thymus peptides should be combined at all.

Common questions about thymosin alpha-1

Is thymosin alpha-1 FDA-approved? Is it legal to buy?

No, it is not FDA-approved, and it is not on the list of ingredients US pharmacies may use for compounding; FDA advisers voted 17 to 4 against adding it in December 2024. It is a prescription medicine in Singapore, registered in Indonesia and approved in Italy, but those approvals cover the licensed Zadaxin product for specific uses, not research powders. [105], [106], [2] See the dated legal-status summary.

Is thymosin alpha-1 the same as TB-500 or thymosin beta-4?

No. All three names come from thymus research, but thymosin alpha-1 is a 28-amino-acid immune peptide, while thymosin beta-4 is a different protein and TB-500 is a short fragment of it, marketed for tissue repair. Only thymosin beta-4 and its derivatives, such as TB-500, are named on the anti-doping list. [1], [101], [113] See how they compare.

How long does thymosin alpha-1 take to work?

It depends on what is being measured. In hepatitis B, responses often built up over the 6–12 months after a 6-month course ended; in personal accounts, some people describe changes within days and others notice nothing after months. No study has measured how quickly it helps with colds or allergies. [53], [3], [60] See what people report.

Can thymosin alpha-1 prevent colds, flu or COVID-19?

This has not been shown. No trial has tested it for colds or flu in healthy people, vaccine studies measured antibodies rather than infections, and COVID-19 studies in hospital patients conflict, with one large cohort finding worse recovery. [1], [31], [80] See the COVID-19 evidence.

Is thymosin alpha-1 safe if you have an autoimmune disease?

Nobody knows. There are no trials in autoimmune disease, Italy's label says use must be judged case by case, and people describe flares after starting it. Do not start during a flare, and do not stop a prescribed biologic or immunosuppressant to try it. [1], [14] See the flare question.

Is 1.6 mg twice a week the right dose for everyone?

It is the only adult dose on any label, for hepatitis B and C and flu-vaccine support, and the most common schedule online. Hospital trials used 1.6 mg twice a day for a week, and the one dose comparison found 0.8 mg worked about as well in hepatitis B. No dose has been tested for general immune support. [2], [29], [17] See typical protocols.

Does a two-hour half-life mean daily dosing works better?

Not necessarily. Blood levels fall by half in about 2 hours and are gone within a day, but blood levels, immune-cell effects and clinical outcomes are different measurements, and no study has compared daily with twice-weekly dosing. [3], [47] See twice a week or every day.

Has thymosin alpha-1 been shown to reduce deaths from sepsis?

No. An earlier 361-person trial suggested fewer deaths, but the larger, placebo-controlled TESTS trial of 1,106 people found no difference (23.4% versus 24.1% by day 28). Older summaries quote an uncorrected hazard ratio of 0.99; the corrected figure is 0.97. [26], [29], [76] See the sepsis trials.

Glossary

Plain explanations of the route, dosing, immune and research terms used in this guide. Underlined terms in the text link here.

Acetate salt

A form of a peptide paired with acetate, common in peptide powders. The FDA treats thymosin alpha-1 acetate and the free peptide as separate substances.

Adverse event

A harmful or unwanted medical event reported after someone used a treatment. A report alone does not prove the treatment caused it.

Aggregation

Peptide molecules clumping together. Clumps can make a product weaker and, when injected, more likely to trigger an immune reaction.

ALT (alanine aminotransferase)

A liver enzyme measured in a blood test. It rises when liver cells are damaged or inflamed, for example when the immune system attacks hepatitis B-infected cells.

Amino acid

A small chemical building block. Chains of amino acids make up peptides and proteins.

Animal study

Research in animals such as rats or mice. It shows what a substance does in a living body, but results in people can differ.

Atopy

An inherited tendency to allergic conditions such as hay fever, asthma and eczema. Italy's thymosin alpha-1 label advises caution in people with atopy.

Autoimmune disease

A condition in which the immune system attacks the body's own tissues, such as lupus, rheumatoid arthritis, psoriasis or Hashimoto's thyroiditis.

Bioavailability

The share of a dose that reaches the bloodstream. It can differ greatly between routes, such as an injection, a nasal spray or a swallowed dose.

Biologic

A medicine made from living cells, often an antibody, that blocks a specific part of the immune system. Examples are used for Crohn's disease, psoriasis and rheumatoid arthritis.

Cell study (in vitro)

Research on cells grown in a dish. It gives early clues about biology, but it is far from proof of benefit in people.

Checkpoint inhibitor

A type of cancer immunotherapy that releases the brakes on T cells so they attack tumours. Because it already stimulates the immune system, adding another immune stimulant may raise the risk of immune side effects.

Compounding

When a pharmacy prepares a customized medicine from individual ingredients. In the US, federal lists control which bulk ingredients pharmacies may use.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.

Course and cycle

A course is the period of repeated use, such as 8 weeks. A cycle is a course plus a planned break before any further use.

Dendritic cell

An immune cell that picks up pieces of germs and shows them to T cells, telling them what to attack.

Dose (amount each time)

The amount given on one occasion. A protocol lists both the dose and how often it is given.

Graft-versus-host disease

A complication of stem-cell or bone-marrow transplants in which the donor's immune cells attack the recipient's body.

Half-life

The time it takes for the measured level of a substance in the blood to fall by half. It is not the same as how long an effect lasts.

Hazard ratio

A way of comparing how quickly an event, such as death, happens in two groups. A value of 1 means no difference; 0.97 means almost no difference.

Herx (Herxheimer reaction)

A temporary worsening of symptoms blamed on bacteria dying off during treatment, first described with antibiotics for syphilis. Online, the word is often used for any bad reaction, which is an interpretation, not a diagnosis.

Immunogenicity

The tendency of a substance to make the immune system react against it, for example by forming antibodies. Impurities and clumps in a peptide product can increase it.

Intramuscular (IM)

Injected into a muscle. Italy's label allows it for thymosin alpha-1's vaccine use; the Indonesian label rules it out.

Investigational

Still being studied and not approved by a regulator, such as the FDA, to treat any condition.

Loading phase

A short period of more frequent or larger doses at the start of a course, before a lower maintenance schedule. For example, 1.6 mg daily for a week, then twice a week.

Freeze-dried (lyophilized)

Dried by freezing and removing the water, leaving a powder. Both Zadaxin and research thymosin alpha-1 are sold this way and mixed with liquid before use.

mcg and mg

Micrograms and milligrams. 1 mg equals 1,000 mcg, so the 1.6 mg label dose is 1,600 mcg.

Open-label

A study in which participants and researchers know who is getting the treatment. It is simpler to run but more open to bias than a blinded study.

Orphan designation

A status regulators give to a product being developed for a rare disease, with incentives such as fee reductions. It is not an approval.

Peptide

A short chain of amino acids. Thymosin alpha-1 is a chain of 28.

Pharmacokinetics

How the body absorbs, moves, breaks down and removes a substance.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies.

Preclinical research

Studies done before research in people: cell studies and animal studies.

Reconstitution

Mixing a freeze-dried powder with a liquid so it can be measured. The amount of peptide in the vial and the volume of liquid added together set how much each unit holds.

Registered medicine

A medicine a country's regulator has approved for sale for specific uses, with an official label. Thymosin alpha-1 is registered in countries such as Singapore, Indonesia and Italy, not in the United States.

Research use only

A label on products sold for laboratory research. It does not mean a product is approved, tested for human use or legal to sell as a medicine.

Sepsis

A life-threatening reaction to infection in which the body's response damages its own organs. It is treated in hospital with antibiotics and organ support.

Subcutaneous (SC)

Injected into the fatty layer just under the skin. The licensed thymosin alpha-1 is given this way.

Syringe units

Markings on an insulin syringe that measure volume. On a U-100 syringe, 100 units equal 1 mL. The amount of drug per unit depends on the vial's concentration.

T cell

A white blood cell that matures in the thymus and recognizes and attacks infected or abnormal cells, or directs other immune cells. CD4 and CD8 cells are the main types.

Thymus

A small gland behind the breastbone where T cells mature. It is largest in childhood and shrinks with age.

Titration

Adjusting a dose in steps, usually starting lower and increasing if needed.

Toll-like receptor

A sensor on immune cells that recognizes common features of germs, such as viral genetic material or bacterial cell walls, and switches on an immune response.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport.

Weekly total

All the amounts given in one week, added together. For example, 1.6 mg twice a week is a 3.2 mg weekly total. Similar weekly totals can still mean very different exposure.

Withdrawal and rebound

Withdrawal effects are symptoms caused by stopping a substance. A rebound is a problem returning worse than before after stopping. Neither has been studied for thymosin alpha-1.

Explore more of the research

Go deeper into the cell and animal experiments behind the mechanism claims.

Across this guide, the citations include 40 original scientific papers: 30 human studies and 10 cell, animal and laboratory studies. The optional library below summarizes selected cell and animal papers by question. Laboratory concentrations are often far above blood levels after an injection, so these findings describe what the peptide can do, not what it does in a person.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: published scientific studies, official product labels, regulatory documents, registered clinical-trial plans and published protocol descriptions. We also reviewed public online forums and community education groups where people describe their own experiences with thymosin alpha-1.

The guide cites 130 sources, including 40 original scientific papers. Each type of source answers a different question. Studies show what researchers measured. Labels show how the licensed product is meant to be used. Protocol descriptions show how thymosin alpha-1 is typically used online. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources